At a glance
ClinicalIndex Comparison RecordStandardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Safety and Tolerability of Multiple Ascending Doses of LY2140023 in Subjects With Schizophrenia
In Brief
A Phase 1 clinical trial evaluating LY2140023 and Aripiprazole for Schizophrenia. Completed, enrolled 75 participants across 2 sites.
Detailed Summary
This is an inpatient, open-label, multiple-dose, multicenter study to evaluate the safety and tolerability of LY2140023 given at doses expected to reflect multiples of the anticipated therapeutic exposure under clinical investigation. In the event of poor tolerability in Part A of this study Part B may be conducted to explore higher doses using titration. Participants in both Parts A and B will participate in a 9 day wash-out period of current medication (Study Days 1-9); participants coming into the study on aripiprazole will remain on their current therapy throughout.
Study Details
Timeline
Interventions
Administered orally
Administered orally